Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Kobayashi Kako Manufacturing Unit Now Under Sawai; 170 Staffers Remain for Compensation, Drug Handover
GMP scandal-tainted Kobayashi Kako said on March 31 that it completed the transfer of its manufacturing unit and associated assets the same day to Trust Pharmatech, a subsidiary of generic giant Sawai Group Holdings. Trust Pharmatech was formed as a…
To read the full story
Related Article
- 400 Kobayashi Kako Staffers Move to Trust Pharmatech
April 4, 2022
- Kobayashi Kako Ditches Turnaround Plan with Manufacturing Transfer to Sawai
December 7, 2021
- Sawai to Acquire Kobayashi Kako’s Manufacturing Sites, Staffers
December 3, 2021
- Kobayashi Kako’s 116-Day Suspension Over, but No Timeline for Resumption
June 7, 2021
BUSINESS
- Fuji Curbs Shipments of Simponi, Ranmark Biosimilars Soon after Launch
September 4, 2026
- Leqembi Subcutaneous Autoinjector Approved in China
September 4, 2026
- Nxera Gets US$8.6 Million OX2R Milestone from Centessa
September 4, 2026
- Top Medipal Shareholder Seeks CEO Ouster, Special Dividend
September 4, 2026
- Nipro Grabs Japan Approval for Stelara IV Biosimilar
September 4, 2026
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…